Skip to main content
Clinical Trials/NCT04686955
NCT04686955
Completed
Phase 3

The Efficacy of Patients With Moderate to Severe Atopic Dermatitis Treated With Chinese Herbal Medicine

Taipei Veterans General Hospital, Taiwan2 sites in 1 country19 target enrollmentJanuary 25, 2021

Overview

Phase
Phase 3
Intervention
Xiao-Xian-Gui-Fu-Tang
Conditions
Atopic Dermatitis
Sponsor
Taipei Veterans General Hospital, Taiwan
Enrollment
19
Locations
2
Primary Endpoint
Changes of SCORing Atopic Dermatitis(SCORAD) Index
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

Conduct a clinical trial of integration of Chinese and Western medicine to evaluate whether the association of traditional Chinese medicine therapy has a remission effect on atopic dermatitis, and to explore the remission of lesions after an association of Chinese herbal medicine, and the correlation of syndrome differentiation types before and after treatment with Chinese and Western medicine, with a view to better understand the efficacy of atopic dermatitis in the treatment of the same disease in Traditional Chinese Medicine, and provide another option for patients with atopic dermatitis.

Detailed Description

This examination will be posted at Taipei Veterans General Hospital to recruit 24 participants who meet the inclusion criteria of atopic dermatitis to do the study. After participants agreeing to the clinical study and signing the consent form, the investigators are going to separate them into the A group (12 participants) and the B group (12 participants). The tests are going to take a total of 14 weeks. Participants need to pass the international diagnostic criteria Hannifin and Rajka to be determined as patients with atopic dermatitis. After, participants need test by scoring Atopic Dermatitis Index (SCORAD) to be determined as mild to moderate atopic dermatitis and accept the Wang Qi Traditional Chinese Medical Constitutional Scale (TCMCS), dermatological quality of life index (DLQI) score or children's skin disease quality of life index (CDLQI) score, routine blood tests, liver and kidney function tests, immunological markers associated with atopic dermatitis Diagnosis of (eosinophils count, ECP, and IgE), tongue diagnosis, and pulse diagnosis. After the collection of data is completed, the investigators will be analyzing the data by SPSS version 21 as a two-paired t-test, ANOVA statistical method, and P \<0.05 as a significant result.

Registry
clinicaltrials.gov
Start Date
January 25, 2021
End Date
December 31, 2022
Last Updated
5 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 6 years old to 30 years old.
  • Diagnosis as an atopic dermatitis patient.
  • The score of the SCORAD is over
  • (moderate to severe atopic dermatitis)

Exclusion Criteria

  • Secondary bacterial infections
  • Received oral or intravenous steroid treatment, anti-biotics, phototherapy, or other immunosuppressive therapies in the previous 2 months.
  • Received Chinese herbal medicine treatment or acupuncture.
  • Pregnant woman or current breastfeeding.
  • Who had catastrophes illness now or in the past must be avoided.
  • Can not sign informed consent or can not communicate with the researcher.
  • Abnormal liver enzymes.
  • Abnormal kidney function tests (1.5 times higher than the upper normal limit)

Arms & Interventions

Group A

Group A will receive Xiao-Xian-Gui-Fu-Tang(VGH4) for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 6 weeks.

Intervention: Xiao-Xian-Gui-Fu-Tang

Group A

Group A will receive Xiao-Xian-Gui-Fu-Tang(VGH4) for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 6 weeks.

Intervention: Placebo

Group B

Group B will receive placebo for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the Xiao-Xian-Gui-Fu-Tang (VGH4)for another 6 weeks.

Intervention: Xiao-Xian-Gui-Fu-Tang

Group B

Group B will receive placebo for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the Xiao-Xian-Gui-Fu-Tang (VGH4)for another 6 weeks.

Intervention: Placebo

Outcomes

Primary Outcomes

Changes of SCORing Atopic Dermatitis(SCORAD) Index

Time Frame: week 0, 3, 6, 8, 11, 14

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). Dermatologists may use this tool before and after treatment to determine whether the treatment has been effective.

Changes of Dermatology Life Quality Index(DLQI)

Time Frame: week 0, 3, 6, 8, 11, 14

The DLQI is designed to measure the health-related quality of life of adult patients suffering from a skin disease.

Changes of Children's Dermatology Life Quality Index(CDLQI)

Time Frame: week 0, 3, 6, 8, 11, 14

The Children's Dermatology Life Quality Index (CDLQI) is designed to measure the impact of any skin disease on the lives of children.

Secondary Outcomes

  • Blood test (AST)(week 0, 6, 14)
  • Changes of Constitution in Chinese Medicine Questionnaire(week 0, 6, 14)
  • Blood test (ALT)(week 0, 6, 14)
  • Blood test (Serum Creatinine)(week 0, 6, 14)

Study Sites (2)

Loading locations...

Similar Trials